Prospective Study on the Prevalence of Secondary Hypertension among Hypertensive Patients Visiting a General Outpatient Clinic in Japan
Secondary hypertension (SH) including endocrine hypertension has been reported to be uncommon. We estimated the prevalence of SH among hypertensive patients. We prospectively studied 1,020 hypertensive patients. As an initial screening, we measured plasma aldosterone concentration, plasma renin acti...
Saved in:
Published in | Hypertension Research Vol. 27; no. 3; pp. 193 - 202 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
The Japanese Society of Hypertension
01.03.2004
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Secondary hypertension (SH) including endocrine hypertension has been reported to be uncommon. We estimated the prevalence of SH among hypertensive patients. We prospectively studied 1,020 hypertensive patients. As an initial screening, we measured plasma aldosterone concentration, plasma renin activity, serum cortisol concentration and plasma catecholamine concentration and conducted abdominal ultrasonography (US). As a secondary screening, we performed furosemide plus upright test, captopril renography, dexamethasone suppression test, 24-h urine catecholamine measurement and abdominal CT. Finally, primary aldosteronism with the exception of idiopathic hyperaldosteronism, pheochromocytoma, and Cushing’s syndrome were diagnosed by histopathological examination of surgical specimens. Idiopathic hyperaldosteronism was clinically diagnosed by adrenocorticotrophic hormone (ACTH)-stimulated adrenal venous sampling and renovascular hypertension by renal arteriography. There were 61 patients with primary aldosteronism, 5 with renovascular hypertension, 11 with Cushing’s syndrome, 10 with preclinical Cushing’s syndrome and 6 with pheochromocytoma, and the prevalence of SH was 9.1% among 1,020 hypertensive patients. In 76 (82%) of 93 patients with SH, hypertension was cured or improved after unilateral adrenalectomy, transsphenoidal pituitary adenectomy or percutaneous transluminal angioplasty. With the exception of US and CT, all initial and secondary screening tests were found to be sensitive and specific for differentiating SH from essential hypertension (EH). In conclusion, the measurement of various hormone concentrations was very sensitive for ruling out SH—a condition for which, in the present study, there were few specific signs or symptoms—while CT and US examinations were not always useful for differentiating SH from EH. The prevalence of curable SH among hypertensive subjects was higher in this study, which was conducted by our simple method of screening tests, than in previous reports. Hypertensive patients should be screened for SH and the underlying disease treated appropriately to avoid long-term use of antihypertensive drugs and risks of atherosclerotic complications. (Hypertens Res 2004; 27: 193-202) |
---|---|
AbstractList | Secondary hypertension (SH) including endocrine hypertension has been reported to be uncommon. We estimated the prevalence of SH among hypertensive patients. We prospectively studied 1,020 hypertensive patients. As an initial screening, we measured plasma aldosterone concentration, plasma renin activity, serum cortisol concentration and plasma catecholamine concentration and conducted abdominal ultrasonography (US). As a secondary screening, we performed furosemide plus upright test, captopril renography, dexamethasone suppression test, 24-h urine catecholamine measurement and abdominal CT. Finally, primary aldosteronism with the exception of idiopathic hyperaldosteronism, pheochromocytoma, and Cushing's syndrome were diagnosed by histopathological examination of surgical specimens. Idiopathic hyperaldosteronism was clinically diagnosed by adrenocorticotrophic hormone (ACTH)-stimulated adrenal venous sampling and renovascular hypertension by renal arteriography. There were 61 patients with primary aldosteronism, 5 with renovascular hypertension, 11 with Cushing's syndrome, 10 with preclinical Cushing's syndrome and 6 with pheochromocytoma, and the prevalence of SH was 9.1% among 1,020 hypertensive patients. In 76 (82%) of 93 patients with SH, hypertension was cured or improved after unilateral adrenalectomy, transsphenoidal pituitary adenectomy or percutaneous transluminal angioplasty. With the exception of US and CT, all initial and secondary screening tests were found to be sensitive and specific for differentiating SH from essential hypertension (EH). In conclusion, the measurement of various hormone concentrations was very sensitive for ruling out SH--a condition for which, in the present study, there were few specific signs or symptoms--while CT and US examinations were not always useful for differentiating SH from EH. The prevalence of curable SH among hypertensive subjects was higher in this study, which was conducted by our simple method of screening tests, than in previous reports. Hypertensive patients should be screened for SH and the underlying disease treated appropriately to avoid long-term use of antihypertensive drugs and risks of atherosclerotic complications. Secondary hypertension (SH) including endocrine hypertension has been reported to be uncommon. We estimated the prevalence of SH among hypertensive patients. We prospectively studied 1,020 hypertensive patients. As an initial screening, we measured plasma aldosterone concentration, plasma renin activity, serum cortisol concentration and plasma catecholamine concentration and conducted abdominal ultrasonography (US). As a secondary screening, we performed furosemide plus upright test, captopril renography, dexamethasone suppression test, 24-h urine catecholamine measurement and abdominal CT. Finally, primary aldosteronism with the exception of idiopathic hyperaldosteronism, pheochromocytoma, and Cushing’s syndrome were diagnosed by histopathological examination of surgical specimens. Idiopathic hyperaldosteronism was clinically diagnosed by adrenocorticotrophic hormone (ACTH)-stimulated adrenal venous sampling and renovascular hypertension by renal arteriography. There were 61 patients with primary aldosteronism, 5 with renovascular hypertension, 11 with Cushing’s syndrome, 10 with preclinical Cushing’s syndrome and 6 with pheochromocytoma, and the prevalence of SH was 9.1% among 1,020 hypertensive patients. In 76 (82%) of 93 patients with SH, hypertension was cured or improved after unilateral adrenalectomy, transsphenoidal pituitary adenectomy or percutaneous transluminal angioplasty. With the exception of US and CT, all initial and secondary screening tests were found to be sensitive and specific for differentiating SH from essential hypertension (EH). In conclusion, the measurement of various hormone concentrations was very sensitive for ruling out SH—a condition for which, in the present study, there were few specific signs or symptoms—while CT and US examinations were not always useful for differentiating SH from EH. The prevalence of curable SH among hypertensive subjects was higher in this study, which was conducted by our simple method of screening tests, than in previous reports. Hypertensive patients should be screened for SH and the underlying disease treated appropriately to avoid long-term use of antihypertensive drugs and risks of atherosclerotic complications. (Hypertens Res 2004; 27: 193-202) Secondary hypertension (SH) including endocrine hypertension has been reported to be uncommon. We estimated the prevalence of SH among hypertensive patients. We prospectively studied 1,020 hypertensive patients. As an initial screening, we measured plasma aldosterone concentration, plasma renin activity, serum cortisol concentration and plasma catecholamine concentration and conducted abdominal ultrasonography (US). As a secondary screening, we performed furosemide plus upright test, captopril renography, dexamethasone suppression test, 24-h urine catecholamine measurement and abdominal CT. Finally, primary aldosteronism with the exception of idiopathic hyperaldosteronism, pheochromocytoma, and Cushing's syndrome were diagnosed by histopathological examination of surgical specimens. Idiopathic hyperaldosteronism was clinically diagnosed by adrenocorticotrophic hormone (ACTH)-stimulated adrenal venous sampling and renovascular hypertension by renal arteriography. There were 61 patients with primary aldosteronism, 5 with renovascular hypertension, 11 with Cushing's syndrome, 10 with preclinical Cushing's syndrome and 6 with pheochromocytoma, and the prevalence of SH was 9.1% among 1,020 hypertensive patients. In 76 (82%) of 93 patients with SH, hypertension was cured or improved after unilateral adrenalectomy, transsphenoidal pituitary adenectomy or percutaneous transluminal angioplasty. With the exception of US and CT, all initial and secondary screening tests were found to be sensitive and specific for differentiating SH from essential hypertension (EH). In conclusion, the measurement of various hormone concentrations was very sensitive for ruling out SH--a condition for which, in the present study, there were few specific signs or symptoms--while CT and US examinations were not always useful for differentiating SH from EH. The prevalence of curable SH among hypertensive subjects was higher in this study, which was conducted by our simple method of screening tests, than in previous reports. Hypertensive patients should be screened for SH and the underlying disease treated appropriately to avoid long-term use of antihypertensive drugs and risks of atherosclerotic complications.Secondary hypertension (SH) including endocrine hypertension has been reported to be uncommon. We estimated the prevalence of SH among hypertensive patients. We prospectively studied 1,020 hypertensive patients. As an initial screening, we measured plasma aldosterone concentration, plasma renin activity, serum cortisol concentration and plasma catecholamine concentration and conducted abdominal ultrasonography (US). As a secondary screening, we performed furosemide plus upright test, captopril renography, dexamethasone suppression test, 24-h urine catecholamine measurement and abdominal CT. Finally, primary aldosteronism with the exception of idiopathic hyperaldosteronism, pheochromocytoma, and Cushing's syndrome were diagnosed by histopathological examination of surgical specimens. Idiopathic hyperaldosteronism was clinically diagnosed by adrenocorticotrophic hormone (ACTH)-stimulated adrenal venous sampling and renovascular hypertension by renal arteriography. There were 61 patients with primary aldosteronism, 5 with renovascular hypertension, 11 with Cushing's syndrome, 10 with preclinical Cushing's syndrome and 6 with pheochromocytoma, and the prevalence of SH was 9.1% among 1,020 hypertensive patients. In 76 (82%) of 93 patients with SH, hypertension was cured or improved after unilateral adrenalectomy, transsphenoidal pituitary adenectomy or percutaneous transluminal angioplasty. With the exception of US and CT, all initial and secondary screening tests were found to be sensitive and specific for differentiating SH from essential hypertension (EH). In conclusion, the measurement of various hormone concentrations was very sensitive for ruling out SH--a condition for which, in the present study, there were few specific signs or symptoms--while CT and US examinations were not always useful for differentiating SH from EH. The prevalence of curable SH among hypertensive subjects was higher in this study, which was conducted by our simple method of screening tests, than in previous reports. Hypertensive patients should be screened for SH and the underlying disease treated appropriately to avoid long-term use of antihypertensive drugs and risks of atherosclerotic complications. |
Author | YAMAGUCHI, Kunio SAITO, Jun NISHIKAWA, Tetsuo OMURA, Masao KAKUTA, Yukio |
Author_xml | – sequence: 1 fullname: OMURA, Masao organization: Department of Medicine, Yokohama Rosai Hospital – sequence: 1 fullname: SAITO, Jun organization: Department of Medicine, Yokohama Rosai Hospital – sequence: 1 fullname: YAMAGUCHI, Kunio organization: Department of Urology, Yokohama Rosai Hospital – sequence: 1 fullname: NISHIKAWA, Tetsuo organization: Department of Medicine, Yokohama Rosai Hospital – sequence: 1 fullname: KAKUTA, Yukio organization: Department of Pathology, Yokohama Rosai Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/15080378$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kUtr3DAUhUVISSZJl90WrbrzVA-PJS3bIc2DQAbSZitk6Tqj4JFdSQ7ML-jfrorTIRS60QWd7xy495yh4zAEQOgDJUvKFP283Y8R0pKJJVX8CC0or2VVM1ofowVRtKlUw5tTdJbSMyFMrhQ9Qad0RSThQi7Qr00c0gg2-xfAD3lyezwEnLeANxFeTA_BAh46_AB2CM7EPb7ejxAzhOQLaHZDeHrzVUI2JnsIOeFHn3z2RTb4CgJE0-P7KY-zjNe9D95iH_CtGU24QO860yd4_zrP0Y9vl9_X19Xd_dXN-stdZVdC5oo51tYdU7Jlom5aBx00HCh1THWS1K3gtWlYa4QjzHEg1hlpOXOi7aRRruPn6NOcO8bh5wQp651PFvreBBimpAWVVElGCvjxFZzaHTg9Rr8r6-u_pysAnwFbLpgidNr6XJYbQo7G95oS_acgPRekmdCloOKq_nEdgv_Df53555TNExxoE7O3Pbyh-fwU00G0WxM1BP4biJ-wIA |
CitedBy_id | crossref_primary_10_4236_ojemd_2023_138011 crossref_primary_10_1016_j_ecl_2011_02_002 crossref_primary_10_1097_MAJ_0b013e3181e95587 crossref_primary_10_1007_s12020_022_03205_6 crossref_primary_10_1210_er_2018_00139 crossref_primary_10_14341_probl201561255_77 crossref_primary_10_1111_cen_14467 crossref_primary_10_1007_s10157_006_0420_0 crossref_primary_10_1016_j_maturitas_2013_12_009 crossref_primary_10_1213_ANE_0000000000005070 crossref_primary_10_1155_2017_8295010 crossref_primary_10_35460_2546_1621_2018_0055 crossref_primary_10_1007_s12020_020_02468_1 crossref_primary_10_1002_oby_21442 crossref_primary_10_9794_jspccs_35_46 crossref_primary_10_1053_j_jvca_2010_12_001 crossref_primary_10_1007_s11517_008_0305_3 crossref_primary_10_1016_j_carj_2014_01_001 crossref_primary_10_1016_j_currproblcancer_2014_01_001 crossref_primary_10_2217_ije_14_17 crossref_primary_10_2165_00002018_200730110_00004 crossref_primary_10_1210_clinem_dgaa982 crossref_primary_10_1161_HYPERTENSIONAHA_124_23379 crossref_primary_10_1016_j_surg_2009_11_020 crossref_primary_10_1291_hypres_29_883 crossref_primary_10_1007_s11154_010_9143_3 crossref_primary_10_1007_s00270_022_03155_6 crossref_primary_10_1038_s41440_024_01666_y crossref_primary_10_4244_EIJV9SRA5 crossref_primary_10_1016_S0211_3449_08_73192_8 crossref_primary_10_1007_s40619_023_01394_4 crossref_primary_10_1016_j_ypmed_2016_07_007 crossref_primary_10_1136_jcp_2009_071647 crossref_primary_10_1590_S0004_27302006000100020 crossref_primary_10_1530_EJE_16_0631 crossref_primary_10_1016_j_suc_2019_04_010 crossref_primary_10_1097_HJH_0000000000001578 crossref_primary_10_1073_pnas_1121407109 crossref_primary_10_1038_hr_2014_16 crossref_primary_10_1136_bcr_2016_216209 crossref_primary_10_1007_s11102_015_0634_9 crossref_primary_10_1016_j_rce_2013_04_001 crossref_primary_10_1038_s41440_018_0128_z crossref_primary_10_1161_01_HYP_0000258796_52134_26 crossref_primary_10_1161_HYPERTENSIONAHA_119_14601 crossref_primary_10_38109_2225_1685_2023_1_6_65 crossref_primary_10_1016_j_asjsur_2015_09_002 crossref_primary_10_1016_S1773_035X_22_00249_0 crossref_primary_10_1016_j_jash_2014_08_002 crossref_primary_10_1507_endocrj_EJ13_0060 crossref_primary_10_1161_CIRCULATIONAHA_108_189141 crossref_primary_10_3904_kjm_2017_92_4_387 crossref_primary_10_1038_hr_2010_202 crossref_primary_10_1291_hypres_30_1009 crossref_primary_10_1291_hypres_29_635 crossref_primary_10_1177_02841851211034046 crossref_primary_10_1210_js_2018_00382 crossref_primary_10_1210_js_2018_00260 crossref_primary_10_1016_j_revmed_2019_07_008 crossref_primary_10_1155_2022_9948057 crossref_primary_10_2174_1573402114666180507153549 crossref_primary_10_1007_s40618_024_02453_9 crossref_primary_10_1016_j_coemr_2019_07_001 crossref_primary_10_1507_endocrj_EJ16_0243 crossref_primary_10_1530_EJE_16_0289 crossref_primary_10_1016_j_ijcard_2007_03_002 crossref_primary_10_1210_clinem_dgac701 crossref_primary_10_1155_2016_6894381 crossref_primary_10_1371_journal_pone_0206432 crossref_primary_10_1016_S0212_8241_06_71748_0 crossref_primary_10_14341_probl201258435_41 crossref_primary_10_1016_j_kint_2022_12_021 crossref_primary_10_1111_iju_12029 crossref_primary_10_1507_endocrj_K06_180 crossref_primary_10_2174_1573402115666190416161116 crossref_primary_10_1530_EJE_15_0483 crossref_primary_10_2169_internalmedicine_50_4280 crossref_primary_10_1148_radiol_2015142159 crossref_primary_10_1291_hypres_29_9 crossref_primary_10_1016_j_crad_2012_02_005 crossref_primary_10_7326_M20_0065 crossref_primary_10_1097_HJH_0b013e3283521484 crossref_primary_10_1210_jc_2008_2766 crossref_primary_10_1177_0004563216650463 crossref_primary_10_3389_fonc_2021_724287 crossref_primary_10_1291_hypres_28_379 crossref_primary_10_1016_j_cpcardiol_2024_102791 crossref_primary_10_1291_hypres_30_1263 crossref_primary_10_1634_theoncologist_2012_0410 crossref_primary_10_1161_HYPERTENSIONAHA_119_14063 crossref_primary_10_1210_clinem_dgac379 crossref_primary_10_4158_EP15627_CR crossref_primary_10_1016_j_mce_2019_110657 crossref_primary_10_1007_s11886_021_01609_w crossref_primary_10_1038_jhh_2010_35 crossref_primary_10_1016_j_cqn_2013_02_001 crossref_primary_10_1038_hr_2014_129 crossref_primary_10_14442_jgfm_16_4_292 crossref_primary_10_1507_endocrj_52_435 crossref_primary_10_3390_jcm9103108 crossref_primary_10_1016_j_cpet_2013_08_008 crossref_primary_10_1053_j_jvca_2025_01_020 crossref_primary_10_1007_s40618_017_0743_6 crossref_primary_10_2176_nmc_51_72 crossref_primary_10_1038_s41440_020_0406_4 crossref_primary_10_1007_s12414_015_0035_z crossref_primary_10_1111_iju_13060 crossref_primary_10_1093_eurheartj_eht534 crossref_primary_10_1016_j_cden_2015_08_008 crossref_primary_10_1007_s40618_025_02532_5 crossref_primary_10_1016_S0212_8241_06_71766_2 crossref_primary_10_1210_jc_2008_0125 crossref_primary_10_26442_00403660_2021_04_200678 crossref_primary_10_1016_S0716_8640_10_70569_1 crossref_primary_10_1002_ccr3_6683 crossref_primary_10_1007_s12020_012_9658_3 crossref_primary_10_11622_smedj_2018154 crossref_primary_10_5507_bp_2012_078 crossref_primary_10_1007_s40618_024_02387_2 crossref_primary_10_1016_S1885_5857_08_60143_7 crossref_primary_10_1111_cen_14375 crossref_primary_10_1007_s12020_012_9609_z crossref_primary_10_5551_jat_4010 crossref_primary_10_1210_clinem_dgab348 crossref_primary_10_1161_HYPERTENSIONAHA_120_16429 crossref_primary_10_1016_S1889_1837_06_71631_2 crossref_primary_10_1016_j_cpet_2008_04_003 crossref_primary_10_1016_S0120_5633_11_70201_7 crossref_primary_10_1016_S0140_6736_05_67139_5 crossref_primary_10_3390_ijms23169042 crossref_primary_10_1291_hypres_29_551 crossref_primary_10_1373_clinchem_2007_087114 crossref_primary_10_1111_iju_13844 crossref_primary_10_1111_jch_14014 crossref_primary_10_1530_EJE_15_0651 crossref_primary_10_1210_clinem_dgaa606 crossref_primary_10_1097_HJH_0000000000002891 crossref_primary_10_1210_jendso_bvac049 crossref_primary_10_1159_000540205 crossref_primary_10_1007_s12020_006_0019_y crossref_primary_10_2165_11593690_000000000_00000 crossref_primary_10_1007_s00423_011_0871_y crossref_primary_10_1177_0267659120909770 crossref_primary_10_1210_jc_2008_0139 crossref_primary_10_2174_1874303X01306010058 crossref_primary_10_1007_s12020_024_03935_9 crossref_primary_10_1016_j_cca_2016_12_014 crossref_primary_10_1111_cen_14724 crossref_primary_10_1210_jc_2016_3206 crossref_primary_10_1253_jjcsc_13_1_109 crossref_primary_10_1007_s42000_019_00114_8 crossref_primary_10_1053_j_ackd_2015_03_001 crossref_primary_10_1111_imj_16189 crossref_primary_10_1186_s12872_023_03577_1 crossref_primary_10_38053_acmj_1455488 crossref_primary_10_1007_s00464_021_08662_0 crossref_primary_10_1507_endocrj_EJ12_0052 crossref_primary_10_31083_j_rcm_2020_04_121 crossref_primary_10_1111_hdi_12394 crossref_primary_10_1016_j_jtumed_2020_03_010 crossref_primary_10_1291_hypres_29_S1 crossref_primary_10_1507_endocrj_EJ14_0384 crossref_primary_10_1016_j_orcp_2015_07_004 crossref_primary_10_3389_fendo_2021_609263 crossref_primary_10_1157_13117734 crossref_primary_10_3389_fendo_2019_00766 crossref_primary_10_1038_ncpendmet0837 crossref_primary_10_1155_2018_4920841 crossref_primary_10_1007_s11906_006_0070_3 crossref_primary_10_1080_10641960802443282 crossref_primary_10_2169_internalmedicine_45_1855 crossref_primary_10_1016_j_pop_2012_11_008 crossref_primary_10_1016_j_euf_2015_09_011 crossref_primary_10_1210_clinem_dgae517 crossref_primary_10_1210_clinem_dgaa954 crossref_primary_10_1016_j_jacc_2020_02_052 crossref_primary_10_1097_CCM_0000000000002333 crossref_primary_10_23736_S0391_1977_18_02884_5 crossref_primary_10_1507_endocrj_KR_105 crossref_primary_10_1210_jendso_bvab085 crossref_primary_10_1016_j_nucmedbio_2008_05_005 crossref_primary_10_1007_s40618_020_01197_6 crossref_primary_10_1186_s12301_021_00265_4 crossref_primary_10_1530_EJE_17_0077 crossref_primary_10_1007_s11154_007_9055_z crossref_primary_10_1111_jch_12713 crossref_primary_10_1007_s40292_016_0153_4 crossref_primary_10_3109_08037051_2013_867655 crossref_primary_10_1016_j_jemermed_2017_05_032 crossref_primary_10_4061_2011_598694 crossref_primary_10_4082_kjfm_2010_31_6_420 crossref_primary_10_1016_j_jacc_2022_08_714 crossref_primary_10_1016_j_surg_2006_07_026 crossref_primary_10_1161_CIRCULATIONAHA_114_008544 crossref_primary_10_1161_CIRCRESAHA_116_303647 crossref_primary_10_1210_clinem_dgz293 crossref_primary_10_1161_HYPERTENSIONAHA_114_04619 crossref_primary_10_1016_j_surg_2023_04_010 crossref_primary_10_1373_clinchem_2014_233551 crossref_primary_10_1161_HYPERTENSIONAHA_121_18118 crossref_primary_10_1507_endocrj_EJ19_0498 crossref_primary_10_1159_000515652 crossref_primary_10_1155_2014_794187 crossref_primary_10_1291_hypres_30_1083 crossref_primary_10_1080_10253890701395896 crossref_primary_10_4103_cdrp_cdrp_3_24 crossref_primary_10_2169_internalmedicine_1218_18 crossref_primary_10_1586_eem_12_65 crossref_primary_10_4103_jdap_jdap_43_24 crossref_primary_10_1016_j_steroids_2013_02_005 crossref_primary_10_1093_ajh_hpad022 crossref_primary_10_1097_MD_0000000000000708 crossref_primary_10_1155_2013_321063 crossref_primary_10_1161_HYPERTENSIONAHA_108_189141 crossref_primary_10_1016_j_cca_2010_01_012 crossref_primary_10_1016_j_jccase_2021_08_001 crossref_primary_10_1038_hr_2010_166 crossref_primary_10_1111_jch_14339 crossref_primary_10_2169_internalmedicine_50_4351 crossref_primary_10_4065_84_2_180 crossref_primary_10_1093_ejendo_lvad140 crossref_primary_10_2169_internalmedicine_55_5196 crossref_primary_10_1507_endocrj_EJ19_0262 crossref_primary_10_1097_MED_0b013e32835ef2fd crossref_primary_10_1186_s43044_024_00556_5 crossref_primary_10_1038_s41440_023_01461_1 crossref_primary_10_1007_s00268_014_2461_y crossref_primary_10_1157_13119966 crossref_primary_10_1038_s41371_019_0272_1 crossref_primary_10_1177_145749690409300409 crossref_primary_10_1016_j_nucmedbio_2018_11_002 crossref_primary_10_1097_HJH_0b013e328360ddf6 crossref_primary_10_7314_APJCP_2015_16_12_5031 crossref_primary_10_1080_10641963_2017_1339072 crossref_primary_10_1097_HJH_0000000000001885 crossref_primary_10_1007_s40618_024_02450_y crossref_primary_10_5005_jp_journals_10002_1314 crossref_primary_10_1210_jc_2018_00059 crossref_primary_10_1210_endrev_bnad011 crossref_primary_10_3399_bjgp18X694589 crossref_primary_10_1177_1066896911427036 crossref_primary_10_3389_fendo_2021_605797 crossref_primary_10_3390_cancers14163845 crossref_primary_10_1258_om_2010_090063 crossref_primary_10_2169_naika_96_2539 crossref_primary_10_3390_cancers11030318 crossref_primary_10_1111_j_1365_2753_2012_01873_x crossref_primary_10_1161_CIRCEP_121_007960 crossref_primary_10_1097_MD_0000000000031313 crossref_primary_10_1186_1758_5996_2_71 crossref_primary_10_3390_jcm12030874 crossref_primary_10_1097_HJH_0000000000003252 crossref_primary_10_1097_HJH_0000000000002047 crossref_primary_10_36290_kar_2019_036 crossref_primary_10_1507_endocrj_EJ12_0270 crossref_primary_10_1507_endocrj_EJ13_0353 crossref_primary_10_1038_s41598_023_47967_z crossref_primary_10_17925_EE_2023_19_2_11 crossref_primary_10_38109_2075_082X_2024_4_5_109 crossref_primary_10_1002_ccr3_6932 crossref_primary_10_1038_s41440_021_00663_9 crossref_primary_10_2478_enr_2022_0028 crossref_primary_10_15829_1728_8800_2019_2_84_93 crossref_primary_10_1161_HYPERTENSIONAHA_119_14341 crossref_primary_10_1136_bcr_2020_238380 crossref_primary_10_1111_jch_14558 crossref_primary_10_1186_s12902_020_0490_0 crossref_primary_10_17650_1818_8338_2018_12_1_43_50 crossref_primary_10_1038_hr_2006_143 crossref_primary_10_1097_MED_0b013e3283390f8d crossref_primary_10_1007_s11695_011_0545_4 crossref_primary_10_1007_s13730_017_0299_5 crossref_primary_10_1158_1078_0432_CCR_16_0384 crossref_primary_10_1089_end_2007_9884 crossref_primary_10_1111_jch_12916 crossref_primary_10_4236_ojneph_2016_63012 crossref_primary_10_1007_s11886_014_0528_x crossref_primary_10_1016_j_aan_2016_08_001 crossref_primary_10_1161_HYPERTENSIONAHA_116_08519 crossref_primary_10_4158_EP09023OR crossref_primary_10_2169_internalmedicine_47_0333 crossref_primary_10_1111_jch_12920 crossref_primary_10_1136_bcr_2013_009491 crossref_primary_10_1136_pgmj_2011_118661 crossref_primary_10_1016_j_revmed_2009_08_015 crossref_primary_10_2169_naika_97_2155 crossref_primary_10_2214_AJR_12_9126 crossref_primary_10_3389_fendo_2024_1372683 crossref_primary_10_3904_kjim_2018_231 crossref_primary_10_1097_MED_0000000000000729 crossref_primary_10_1007_s11886_019_1185_x crossref_primary_10_1093_ejendo_lvac016 crossref_primary_10_1016_j_ecl_2019_08_006 crossref_primary_10_1111_j_1442_2042_2012_03014_x crossref_primary_10_1016_j_ecl_2019_08_002 crossref_primary_10_3803_EnM_2020_35_1_157 crossref_primary_10_1038_hr_2013_107 crossref_primary_10_1016_j_beem_2019_101346 crossref_primary_10_1177_0004563217739931 crossref_primary_10_2169_naika_95_482 crossref_primary_10_1016_j_asjsur_2014_01_011 crossref_primary_10_1016_j_steroids_2019_108470 crossref_primary_10_1053_j_jvca_2021_03_034 crossref_primary_10_3389_fendo_2022_861581 crossref_primary_10_1507_endocrj_K07E_164 crossref_primary_10_1016_j_surg_2018_05_085 crossref_primary_10_1007_s00423_021_02245_2 crossref_primary_10_1016_S1889_1837_06_71658_0 crossref_primary_10_1016_S1479_666X_07_80026_6 crossref_primary_10_1186_1532_429X_14_28 crossref_primary_10_1016_j_plabm_2016_05_001 crossref_primary_10_1507_endocrj_EJ12_0247 crossref_primary_10_1016_j_jvir_2013_01_007 crossref_primary_10_1016_j_beem_2006_07_011 crossref_primary_10_1007_s11906_012_0246_y crossref_primary_10_1007_s40618_020_01484_2 crossref_primary_10_1177_2054270417698632 crossref_primary_10_1507_endocrj_EJ11_0133 crossref_primary_10_11622_smedj_2021135 crossref_primary_10_23736_S2724_5276_18_05319_7 crossref_primary_10_1245_s10434_012_2670_2 crossref_primary_10_1080_10408360600931831 crossref_primary_10_2169_naika_101_605 crossref_primary_10_1016_j_beem_2019_101365 crossref_primary_10_1177_2048004021992191 crossref_primary_10_1210_jc_2016_1673 crossref_primary_10_1507_endocrj_K10E_402 crossref_primary_10_1507_endocrj_EJ22_0585 crossref_primary_10_1007_s12349_009_0053_4 crossref_primary_10_1016_j_eprac_2020_10_016 crossref_primary_10_1097_HJH_0b013e328362152e crossref_primary_10_1111_1556_4029_12107 crossref_primary_10_3389_fonc_2022_979994 crossref_primary_10_1016_j_med_2020_10_013 crossref_primary_10_4236_ojrad_2017_74024 crossref_primary_10_1186_s40981_018_0212_z crossref_primary_10_1210_js_2019_00226 crossref_primary_10_1038_s41440_021_00710_5 crossref_primary_10_1038_nrendo_2011_51 crossref_primary_10_1007_s40292_018_0288_6 crossref_primary_10_4137_JCM_S6316 crossref_primary_10_1016_j_cca_2017_12_026 crossref_primary_10_1053_j_ackd_2019_03_002 crossref_primary_10_1291_hypres_30_103 crossref_primary_10_1111_j_1742_7843_2011_00758_x crossref_primary_10_1007_s12020_011_9588_5 crossref_primary_10_1186_1471_2261_12_38 crossref_primary_10_1631_jzus_B1600411 crossref_primary_10_1507_endocrj_K09E_014 crossref_primary_10_2169_internalmedicine_0891_18 crossref_primary_10_1186_s12957_019_1649_x crossref_primary_10_1210_jc_2019_00996 crossref_primary_10_1016_j_cvsm_2009_10_005 crossref_primary_10_1016_j_ando_2022_02_001 crossref_primary_10_1291_hypres_30_111 crossref_primary_10_1007_s12020_017_1300_y crossref_primary_10_1007_s00268_005_0594_8 crossref_primary_10_1210_jc_2014_1498 |
Cites_doi | 10.1053/meta.2002.30498 10.1016/0002-9343(65)90122-1 10.1016/S0025-6196(11)62105-8 10.1097/00004872-199715010-00006 10.1536/ihj.26.549 10.1097/00004872-200306000-00001 10.1291/hypres.24.613 10.1016/S0140-6736(00)04223-9 10.1291/hypres.25.553 10.3109/10641968109037426 10.1001/archinte.147.7.1289 10.1148/radiology.212.2.r99au20378 10.1111/j.0954-6820.1981.tb11628.x 10.1210/jc.86.8.4003 10.1016/S0753-3322(00)80019-0 10.1046/j.1365-2265.2002.01613.x 10.1093/qjmed/90.1.51 10.1001/archinte.141.12.1589 10.1097/00004872-199405000-00015 10.1097/00004872-199816100-00018 10.1016/S0140-6736(00)04172-6 10.1210/jc.85.5.1863 10.1001/archinte.1965.03870020012006 10.1001/jama.289.18.2363 10.1016/S0895-7061(02)02969-2 10.1002/ccd.10387 10.1016/S0889-8529(02)00013-0 10.1093/ndt/gfg121 10.1210/jc.86.9.4292 10.1111/j.1440-1681.1994.tb02519.x 10.1161/01.HYP.0000038478.59760.41 10.1210/jc.85.8.2854 |
ContentType | Journal Article |
Copyright | 2004 by the Japanese Society of Hypertension |
Copyright_xml | – notice: 2004 by the Japanese Society of Hypertension |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1291/hypres.27.193 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1348-4214 |
EndPage | 202 |
ExternalDocumentID | 15080378 10_1291_hypres_27_193 article_hypres_27_3_27_3_193_article_char_en |
Genre | Journal Article |
GroupedDBID | --- -Q- .55 0R~ 29I 2WC 39C 4.4 406 53G 5GY 70F 7X7 88E 8FI 8FJ AACDK AANZL AASML AATNV ABAKF ABAWZ ABBRH ABDBE ABFSG ABJNI ABLJU ABRTQ ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACMJI ACRQY ACSTC ACZOJ ADBBV AEFQL AEJRE AEMSY AENEX AESKC AEVLU AEXYK AEZWR AFBBN AFDZB AFHIU AFKRA AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AHWEU AIGIU AILAN AIXLP AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMYLF ATHPR AXYYD AYFIA BAWUL BENPR BKKNO BPHCQ BVXVI CCPQU CS3 DIK DNIVK DPUIP DU5 E3Z EBLON EBS EE. EIOEI EJD EMB EMOBN F5P FDQFY FERAY FIGPU FIZPM FSGXE FYUFA GX1 HMCUK HZ~ IWAJR JSF JSH JSO JZLTJ KQ8 LGEZI LOTEE M1P NADUK NQJWS NXXTH O9- OK1 P2P PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RJT RNT RNTTT ROL RZJ SNX SNYQT SOHCF SOJ SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TKC TR2 TSG UKHRP W2D X7M XSB AAYXX ACMFV ALIPV CITATION 3V. AAZLF ADHDB CGR CUY CVF ECM EIF NAO NPM 7X8 |
ID | FETCH-LOGICAL-c578t-2d2b4f298b2746bdefe63e11d29f804b734a62ba7d02d3e0cda8c32d7bf8a9df3 |
ISSN | 0916-9636 |
IngestDate | Fri Jul 11 01:23:26 EDT 2025 Wed Feb 19 01:37:53 EST 2025 Tue Jul 01 01:54:25 EDT 2025 Thu Apr 24 23:08:42 EDT 2025 Wed Sep 03 06:30:03 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c578t-2d2b4f298b2746bdefe63e11d29f804b734a62ba7d02d3e0cda8c32d7bf8a9df3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.jstage.jst.go.jp/article/hypres/27/3/27_3_193/_article/-char/en |
PMID | 15080378 |
PQID | 71819820 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_71819820 pubmed_primary_15080378 crossref_citationtrail_10_1291_hypres_27_193 crossref_primary_10_1291_hypres_27_193 jstage_primary_article_hypres_27_3_27_3_193_article_char_en |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2004-03-01 |
PublicationDateYYYYMMDD | 2004-03-01 |
PublicationDate_xml | – month: 03 year: 2004 text: 2004-03-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Hypertension Research |
PublicationTitleAlternate | Hypertension Research |
PublicationYear | 2004 |
Publisher | The Japanese Society of Hypertension |
Publisher_xml | – name: The Japanese Society of Hypertension |
References | 36. Morganti A: Angioplasty of the renal artery: antihypertensive and renal effects. J Nephrol 2000; 13 (Suppl): S28-S33. 18. Ross EJ: Conn’s syndrome due to adrenal hyperplasia with hypertrophy of zona glomerulosa, relieved by unilateral adrenalectomy. Am J Med 1965; 39: 994-1001. 6. Gordon RD, Stowasser M, Tunny TJ, et al: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315-318. 15. Nugent CA, Nicholis T, Tyler FH: Diagnosis of Cushing’s syndrome: single dose dexamethasone suppression test. Arch Intern Med 1965; 116: 172-176. 22. Boscaro M, Barzon L, Fallo F, et al: Cushing’s syndrome. Lancet 2001; 357: 783-791. 2. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension: Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24: 613-634. 13. Mikami K, Nishikawa T, Tamura Y, et al: Inter-relationship of sympathetic nervous system and renin-angiotensin-aldosterone system in three renin subgroups of borderline and persistent essential hypertension. Clin Exp Hypertens 1981; 3: 1091-1107. 27. Fardella CE, Mosso L, Gómez-Sánchez C, et al: Primary aldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867. 32. Yamashita T, Ito F, Iwakiri N, et al: Prevalence and predictors of renal artery stenosis in patients undergoing cardiac catheterization. Hypertens Res 2002; 25: 553-557. 35. Xue F, Bettmann MA, Langdon DR, et al: Outcome and cost comparison of percutaneous transluminal renal angioplasty, renal arterial stent placement, and renal arterial bypass grafting. Radiology 1999; 212: 378-384. 19. Guideline Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053. 16. Naomi S, Iwaoka T, Umeda T, et al: Clinical evaluation of captopril screening test for primary aldosteronism. Jpn Heart J 1985; 26: 549-556. 4. Danielson M, Dammström B: The prevalence of secondary and curable hypertension. Acta Med Scand 1981; 209: 451-455. 12. Anderson GH Jr, Blakeman N, Streeten DHP: The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994; 12: 609-615. 25. Montori VM, Schwartz GL, Chapman AB, et al: Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001: 76: 877-882. 10. Rossi E, Regolisti G, Negro A, et al: High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15: 896-902. 28. Hirohara D, Nomura K, Okamoto T, et al: Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives. J Clin Endocrinol Metab 2001; 86: 4292-4298. 17. Omura M, Sasano H, Fujiwara T, et al: Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selected adrenal venous sampling. Metabolism 2002; 51: 350-355. 29. Montori VM, Young WF Jr: Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism: a systematic review of the literature. Endocrinol Metab Clin North Am 2002; 31: 619-632. 7. Komiya I, Yamada T, Takasu N, et al: An abnormal sodium metabolism in Japanese patients with essential hypertension, judged by serum sodium distribution, renal function and the renin-aldosterone system. J Hypertens 1997; 15: 65-72. 3. Rudnick KV, Sackett DL, Hirst S, et al: Hypertension in a family practice. Can Med Assoc J 1977; 117: 492-497. 1. Wolf-Maier K, Cooper RS, Banegas JR, et al: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-2369. 5. Sinclair AM, Isles CG, Brown I, et al: Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987; 147: 1289-1293. 26. Hiramatsu K, Yamada T, Yukimura Y, et al: A screening test to identify aldosterone-producing adenoma by measurement plasma renin activity. Arch Intern Med 1981; 141: 1589-1593. 14. Helin KH, Tikkanen I, von Knorring JE, et al: Screening for renovascular hypertension in a population with relatively low prevalence. J Hypertens 1998; 16: 1523-1529. 31. Van Ampting JM, Penne EL, Beek FJ, et al: Prevalence of atherosclerotic renal artery stenosis in patients starting dialysis. Nephrol Dial Transplant 2003; 18: 1147-1151. 24. Seifarth C, Trenkel S, Schobel H, et al: Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol (Oxf) 2002; 57: 457-465. 8. Lim PO, Rodgers P, Cardale K, et al: Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999; 353: 40. 11. Nishikawa T, Omura M: Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 2000; 54 (Suppl 1): 83s-85s. 21. Loh KC, Shlossberg AH, Abbott EC, et al: Phaeochromocytoma: a ten-year survey. QJM 1997; 90: 51-60. 23. Mulatero P, Rabbia F, Milan A, et al: Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40: 897-902. 33. Khosla S, Kunjummen B, Manda R, et al: Prevalence of renal artery stenosis requiring revascularization in patients initially referred for coronary angiography. Cathet Cardiovasc Intervent 2003; 58: 400-403. 20. Fardella CE, Mosso L: Author’s response; prevalence of primary aldosteronism in unselected hypertensive populations: screening and definitive diagnosis. J Clin Endocrinol Metab 2001; 86: 4003-4004. 30. Kaplan NM: Caution over the current epidemic of primary aldosteronism. Lancet 2001; 357: 953-954. 9. Loh K, Koay E, Khaw M, et al: Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-2859. 34. Martinez-Amenos A, Rama H, Sarrias X, et al: Percutaneous transluminal angioplasty in the treatment of renovascular hypertension. J Hum Hypertens 1991; 5: 97-100. 22 23 24 Montori VM, Schwartz GL, Chapman AB (25) 2001; 76 26 (6) 1994; 21 27 Lim PO, Rodgers P, Cardale K, et al (8) 1999; 353 28 Rudnick KV, Sackett DL, Hirst S, et (3) 1977; 117 Montori VM, Young WF Jr (29) 2002; 31 Xue F, Bettmann MA, Langdon DR, et (35) 1999; 212 Mikami K, Nishikawa T, Tamura Y, et (13) 1981; 3 Loh KC, Shlossberg AH, Abbott EC, e (21) 1997; 90 Nugent CA, Nicholis T, Tyler FH (15) 1965; 116 Anderson GH Jr, Blakeman N, Streete (12) 1994; 12 NAOMI S (16) 1985; 26 30 10 32 14 17 18 19 Nishikawa T, Omura M (11) 2000; 54 (Suppl 1) Khosla S, Kunjummen B, Manda R, et (33) 2003; 58 1 Danielson M, Dammström B (4) 1981; 209 Martinez-Amenos A, Rama H, Sarrias (34) 1991; 5 5 7 Morganti A (36) 2000; 13(Suppl) Van Ampting JM, Penne EL, Beek FJ (31) 2003; 18 9 Japanese Society of Hypertension Gu (2) 2001; 24 20 |
References_xml | – reference: 1. Wolf-Maier K, Cooper RS, Banegas JR, et al: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-2369. – reference: 22. Boscaro M, Barzon L, Fallo F, et al: Cushing’s syndrome. Lancet 2001; 357: 783-791. – reference: 10. Rossi E, Regolisti G, Negro A, et al: High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15: 896-902. – reference: 3. Rudnick KV, Sackett DL, Hirst S, et al: Hypertension in a family practice. Can Med Assoc J 1977; 117: 492-497. – reference: 13. Mikami K, Nishikawa T, Tamura Y, et al: Inter-relationship of sympathetic nervous system and renin-angiotensin-aldosterone system in three renin subgroups of borderline and persistent essential hypertension. Clin Exp Hypertens 1981; 3: 1091-1107. – reference: 29. Montori VM, Young WF Jr: Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism: a systematic review of the literature. Endocrinol Metab Clin North Am 2002; 31: 619-632. – reference: 24. Seifarth C, Trenkel S, Schobel H, et al: Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol (Oxf) 2002; 57: 457-465. – reference: 8. Lim PO, Rodgers P, Cardale K, et al: Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999; 353: 40. – reference: 4. Danielson M, Dammström B: The prevalence of secondary and curable hypertension. Acta Med Scand 1981; 209: 451-455. – reference: 20. Fardella CE, Mosso L: Author’s response; prevalence of primary aldosteronism in unselected hypertensive populations: screening and definitive diagnosis. J Clin Endocrinol Metab 2001; 86: 4003-4004. – reference: 17. Omura M, Sasano H, Fujiwara T, et al: Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selected adrenal venous sampling. Metabolism 2002; 51: 350-355. – reference: 27. Fardella CE, Mosso L, Gómez-Sánchez C, et al: Primary aldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867. – reference: 2. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension: Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24: 613-634. – reference: 14. Helin KH, Tikkanen I, von Knorring JE, et al: Screening for renovascular hypertension in a population with relatively low prevalence. J Hypertens 1998; 16: 1523-1529. – reference: 30. Kaplan NM: Caution over the current epidemic of primary aldosteronism. Lancet 2001; 357: 953-954. – reference: 9. Loh K, Koay E, Khaw M, et al: Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-2859. – reference: 35. Xue F, Bettmann MA, Langdon DR, et al: Outcome and cost comparison of percutaneous transluminal renal angioplasty, renal arterial stent placement, and renal arterial bypass grafting. Radiology 1999; 212: 378-384. – reference: 28. Hirohara D, Nomura K, Okamoto T, et al: Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives. J Clin Endocrinol Metab 2001; 86: 4292-4298. – reference: 26. Hiramatsu K, Yamada T, Yukimura Y, et al: A screening test to identify aldosterone-producing adenoma by measurement plasma renin activity. Arch Intern Med 1981; 141: 1589-1593. – reference: 33. Khosla S, Kunjummen B, Manda R, et al: Prevalence of renal artery stenosis requiring revascularization in patients initially referred for coronary angiography. Cathet Cardiovasc Intervent 2003; 58: 400-403. – reference: 7. Komiya I, Yamada T, Takasu N, et al: An abnormal sodium metabolism in Japanese patients with essential hypertension, judged by serum sodium distribution, renal function and the renin-aldosterone system. J Hypertens 1997; 15: 65-72. – reference: 11. Nishikawa T, Omura M: Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 2000; 54 (Suppl 1): 83s-85s. – reference: 31. Van Ampting JM, Penne EL, Beek FJ, et al: Prevalence of atherosclerotic renal artery stenosis in patients starting dialysis. Nephrol Dial Transplant 2003; 18: 1147-1151. – reference: 23. Mulatero P, Rabbia F, Milan A, et al: Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40: 897-902. – reference: 34. Martinez-Amenos A, Rama H, Sarrias X, et al: Percutaneous transluminal angioplasty in the treatment of renovascular hypertension. J Hum Hypertens 1991; 5: 97-100. – reference: 16. Naomi S, Iwaoka T, Umeda T, et al: Clinical evaluation of captopril screening test for primary aldosteronism. Jpn Heart J 1985; 26: 549-556. – reference: 21. Loh KC, Shlossberg AH, Abbott EC, et al: Phaeochromocytoma: a ten-year survey. QJM 1997; 90: 51-60. – reference: 32. Yamashita T, Ito F, Iwakiri N, et al: Prevalence and predictors of renal artery stenosis in patients undergoing cardiac catheterization. Hypertens Res 2002; 25: 553-557. – reference: 25. Montori VM, Schwartz GL, Chapman AB, et al: Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001: 76: 877-882. – reference: 6. Gordon RD, Stowasser M, Tunny TJ, et al: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315-318. – reference: 12. Anderson GH Jr, Blakeman N, Streeten DHP: The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994; 12: 609-615. – reference: 36. Morganti A: Angioplasty of the renal artery: antihypertensive and renal effects. J Nephrol 2000; 13 (Suppl): S28-S33. – reference: 18. Ross EJ: Conn’s syndrome due to adrenal hyperplasia with hypertrophy of zona glomerulosa, relieved by unilateral adrenalectomy. Am J Med 1965; 39: 994-1001. – reference: 15. Nugent CA, Nicholis T, Tyler FH: Diagnosis of Cushing’s syndrome: single dose dexamethasone suppression test. Arch Intern Med 1965; 116: 172-176. – reference: 5. Sinclair AM, Isles CG, Brown I, et al: Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987; 147: 1289-1293. – reference: 19. Guideline Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053. – ident: 17 doi: 10.1053/meta.2002.30498 – ident: 18 doi: 10.1016/0002-9343(65)90122-1 – volume: 76 start-page: 877 issn: 0025-6196 year: 2001 ident: 25 publication-title: Mayo Clin Proc doi: 10.1016/S0025-6196(11)62105-8 – ident: 7 doi: 10.1097/00004872-199715010-00006 – volume: 26 start-page: 549 issn: 0021-4868 issue: 4 year: 1985 ident: 16 publication-title: Jpn Heart J doi: 10.1536/ihj.26.549 – ident: 19 doi: 10.1097/00004872-200306000-00001 – volume: 5 start-page: 97 issn: 0950-9240 year: 1991 ident: 34 publication-title: J Hum Hypertens – volume: 24 start-page: 613 issn: 0916-9636 year: 2001 ident: 2 publication-title: Hypertens Res doi: 10.1291/hypres.24.613 – ident: 30 doi: 10.1016/S0140-6736(00)04223-9 – ident: 32 doi: 10.1291/hypres.25.553 – volume: 3 start-page: 1091 issn: 0730-0077 year: 1981 ident: 13 publication-title: Clin Exp Hypertens doi: 10.3109/10641968109037426 – ident: 5 doi: 10.1001/archinte.147.7.1289 – volume: 212 start-page: 378 issn: 0033-8419 year: 1999 ident: 35 publication-title: Radiology doi: 10.1148/radiology.212.2.r99au20378 – volume: 209 start-page: 451 issn: 0001-6101 year: 1981 ident: 4 publication-title: Acta Med Scand doi: 10.1111/j.0954-6820.1981.tb11628.x – ident: 20 doi: 10.1210/jc.86.8.4003 – volume: 54 (Suppl 1) start-page: 83s issn: 0753-3322 year: 2000 ident: 11 publication-title: Biomed Pharmacother doi: 10.1016/S0753-3322(00)80019-0 – ident: 24 doi: 10.1046/j.1365-2265.2002.01613.x – volume: 90 start-page: 51 issn: 1460-2725 year: 1997 ident: 21 publication-title: QJM doi: 10.1093/qjmed/90.1.51 – ident: 26 doi: 10.1001/archinte.141.12.1589 – volume: 12 start-page: 609 issn: 0263-6352 year: 1994 ident: 12 publication-title: J Hypertens doi: 10.1097/00004872-199405000-00015 – volume: 117 start-page: 492 issn: 0820-3946 year: 1977 ident: 3 publication-title: Can Med Assoc J – ident: 14 doi: 10.1097/00004872-199816100-00018 – ident: 22 doi: 10.1016/S0140-6736(00)04172-6 – ident: 27 doi: 10.1210/jc.85.5.1863 – volume: 116 start-page: 172 issn: 0003-9926 year: 1965 ident: 15 publication-title: Arch Intern Med doi: 10.1001/archinte.1965.03870020012006 – ident: 1 doi: 10.1001/jama.289.18.2363 – ident: 10 doi: 10.1016/S0895-7061(02)02969-2 – volume: 58 start-page: 400 year: 2003 ident: 33 publication-title: Cathet Cardiovasc Intervent doi: 10.1002/ccd.10387 – volume: 31 start-page: 619 issn: 0889-8529 year: 2002 ident: 29 publication-title: Endocrinol Metab Clin North Am doi: 10.1016/S0889-8529(02)00013-0 – volume: 18 start-page: 1147 issn: 0931-0509 year: 2003 ident: 31 publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfg121 – ident: 28 doi: 10.1210/jc.86.9.4292 – volume: 21 start-page: 315 issn: 0305-1870 issue: 4 year: 1994 ident: 6 publication-title: Clin Exp Pharmacol Physiol doi: 10.1111/j.1440-1681.1994.tb02519.x – ident: 23 doi: 10.1161/01.HYP.0000038478.59760.41 – volume: 353 start-page: 40 issn: 0140-6736 year: 1999 ident: 8 publication-title: Lancet – ident: 9 doi: 10.1210/jc.85.8.2854 – volume: 13(Suppl) start-page: S28 issn: 1120-3625 year: 2000 ident: 36 publication-title: J Nephrol |
SSID | ssj0028591 |
Score | 2.2725716 |
Snippet | Secondary hypertension (SH) including endocrine hypertension has been reported to be uncommon. We estimated the prevalence of SH among hypertensive patients.... |
SourceID | proquest pubmed crossref jstage |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 193 |
SubjectTerms | Adrenal Gland Diseases - diagnosis Adrenal Gland Diseases - surgery Adrenal Gland Neoplasms - complications Adrenal Gland Neoplasms - diagnosis Adrenal Gland Neoplasms - surgery Adrenalectomy Ambulatory Care Facilities - statistics & numerical data Angioplasty, Balloon Cushing Syndrome - complications Cushing Syndrome - diagnosis Cushing Syndrome - surgery Cushing’s syndrome Humans Hyperaldosteronism - complications Hyperaldosteronism - diagnosis Hyperaldosteronism - surgery Hypertension - epidemiology Hypertension - etiology Hypertension, Renovascular - diagnosis Hypertension, Renovascular - therapy Mass Screening pheochromocytoma Pheochromocytoma - complications Pheochromocytoma - diagnosis Pheochromocytoma - surgery Pituitary Gland - surgery Prevalence primary aldosteronism Prospective Studies renovascular hypertension secondary hypertension Sensitivity and Specificity Treatment Outcome |
Title | Prospective Study on the Prevalence of Secondary Hypertension among Hypertensive Patients Visiting a General Outpatient Clinic in Japan |
URI | https://www.jstage.jst.go.jp/article/hypres/27/3/27_3_193/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/15080378 https://www.proquest.com/docview/71819820 |
Volume | 27 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Hypertension Research, 2004, Vol.27(3), pp.193-202 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgQYgL4k15-oC4lCyJ48aJOCHYVdnd7nJope4psmNnKcsmqE0u_AH-NuNHnFSw4nGJKmfqpPk-T2cmnhmEXgolMhoWRcDlhAcUHADQg4IGE8Z0wTldgE8H9GfHyXRBD5aTZR_KNtkljdgtvv82r-R_UIUxwFVnyf4Dsn5SGIDPgC8cAWE4_hXGn9Z1lylp68S60L_O_IfrmEULxuBGO71Sb4_7DF7n2uxZ15uQTZ-hfggmcVVWN2Odcm42RHPdY1nHrcZ127jTLp1Sh0oO4L-2Ghq40-EVXCUhH3E-uWhNW6PxjG947YM7fNXY9z-tZ-opv-Bnuk-LUURttfLSh_y8tRbvaXvuhruoBe23bXXhxygJYPEnQ01sqwQ4xsUDtRrZLoq_qHuSaXUPDwp-zy5hu05uu6z28Um-vzg6yud7y_lVdI2AP6FbXXz4eOg9c13EzxRldDflirHC9G-2Jt8yXq5_Afv9TF3umhgTZX4b3XK-BX5niXIHXVHVXXRj5nZP3EM_BnzBhi-4rjDwBfd8wXWJPV_wkC_Y8AUP-YI7vuCOL5hjxxfc8wVbvuBVhQ1f7qPF_t78_TRwjTiCAhR6ExBJBC1JlgrCaCKkKlUSqyiSJCvTkAoWU54QwZkMiYxVWEieFjGRTJQpz2QZP0A7VV2pRwjLiIiERykFFUHTpBBcMRWnKiqzMGVZMUKvuyecF65KvW6W8jXX3ioAkltAcsJyAGSEXnnxb7Y8y2WCby1cXsyt2oFYbA8g7U_q1EfQNCP0osM4B_Wr36nxStXtJgfTLsrAih6hhxb6_jbA9Qljlj7-43efoJv9EnmKdpp1q56BqduI54amPwGHz7jj |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prospective+study+on+the+prevalence+of+secondary+hypertension+among+hypertensive+patients+visiting+a+general+outpatient+clinic+in+Japan&rft.jtitle=Hypertension+research&rft.au=Omura%2C+Masao&rft.au=Saito%2C+Jun&rft.au=Yamaguchi%2C+Kunio&rft.au=Kakuta%2C+Yukio&rft.date=2004-03-01&rft.issn=0916-9636&rft.volume=27&rft.issue=3&rft.spage=193&rft_id=info:doi/10.1291%2Fhypres.27.193&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0916-9636&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0916-9636&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0916-9636&client=summon |